Repligen Corporation (RGEN)
Payables turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Cost of revenue | US$ in thousands | 359,794 | 354,517 | 345,830 | 279,280 | 156,634 |
Payables | US$ in thousands | — | — | — | — | — |
Payables turnover | — | — | — | — | — |
December 31, 2024 calculation
Payables turnover = Cost of revenue ÷ Payables
= $359,794K ÷ $—K
= —
Based on the data provided, Repligen Corporation's payables turnover ratio is not available for the years 2020 to 2024. The payables turnover ratio is a liquidity metric that measures how efficiently a company manages its outstanding supplier obligations or accounts payable. Without specific values for the payables turnover ratio, it is challenging to assess Repligen Corporation's ability to pay its suppliers in a timely manner. Further information or historical trend analysis would be necessary to provide a more thorough evaluation of the company's payables turnover performance.
Peer comparison
Dec 31, 2024
Company name
Symbol
Payables turnover
Repligen Corporation
RGEN
—
ADMA Biologics Inc
ADMA
10.23
Amgen Inc
AMGN
—
Bio-Techne Corp
TECH
25.82
Biogen Inc
BIIB
12.10
Gilead Sciences Inc
GILD
—
Halozyme Therapeutics Inc
HALO
—
Krystal Biotech Inc
KRYS
22.81
Moderna Inc
MRNA
—
Neurocrine Biosciences Inc
NBIX
—
Vericel Corp Ord
VCEL
—